FDA/Industry Least Burdensome Collaboration To Follow Release Of Guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA will meet with industry to discuss the agency's implementation of least burdensome requirements for premarket submissions, following the pending release of a draft guidance document.
You may also be interested in...
FDA Approach To Least Burdensome Critiqued By Device Industry Task Force
FDA's use of postmarket studies as a condition of approval for two transmyocardial revascularization devices is a fitting example of how to apply the "least burdensome" principles to the device review process as mandated by the 1997 FDA Modernization Act, suggests a coalition of medical device organizations.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.